Protea Announces Collaborative Partnership With Protein Metrics

Protea to Use Novel Proteomics Software to Support Biopharma Research

Morgantown, West Virginia, UNITED STATES

MORGANTOWN, W. Va., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today it is collaborating with Protein Metrics Inc., a premier provider of software solutions for the comprehensive characterization of proteins, to advance new analytical capabilities for use in the development of protein biotherapeutics.

“We are positioning Protea to be a leader in the next generation of bioanalytics, focused on the needs of the biotherapeutics industry,” stated Greg Kilby, Ph.D., Protea’s Vice President and Chief Operating Officer. He added, “Our Protein Metrics collaboration will provide Protea access to advanced software for comprehensive protein characterization, PTM analysis, and sequence variant analysis.  We will combine our technologies, including our proprietary LAESI mass spec imaging platform, with Protein Metrics software to provide novel, ‘big data’ services to identify, characterize, and quantify biologically important molecules. Biopharma is in need of these new bioanalytical capabilities.”

Chris Becker, President and CEO of Protein Metrics, commented that, “The rapid adoption of our suite of software is entirely thanks to the input from our customers who have helped us design tools that are directly applicable and tailored to their needs.  We are delighted to partner with Protea Biosciences and are looking forward to seeing our software advance the results they provide their clients.”

About Protea Biosciences Group, Inc.
Protea Biosciences Group, Inc. (OTCQB:PRGB) provides innovative bioanalytical solutions to the pharmaceutical and life science industries by applying the Company's proprietary technology to identify and characterize the proteins, metabolites, lipids and other biologically-active molecules which are the byproducts of all living cells and life forms. Protea is the leader in mass spectrometry imaging services (MSI), providing a revolutionary capability that enables the identification and spatial display of biologically-active molecules in tissue and cells. MSI can be performed without sample preparation, labeling or antibody techniques, thereby integrating for the first time direct identification of molecules with anatomic pathology.

About Protein Metrics
Protein Metrics Inc. is a privately held company serving biopharmaceutical development professionals. The company focuses on the analysis of mass spectrometric and other analytical data on proteins, peptides and glycans. Seeking to ensure that software to analyze mass spec and other analytical data keeps pace with the rapid advances in instrumentation, Protein Metrics leverages its experience in mass spectrometry, computer science, and bioinformatics to make analytical results more complete, sensitive, accurate, and easier to achieve.  The company is headquartered in San Carlos, California.  For more information, visit

Forward-Looking Statements 
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar importance may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more Information:          
Protea Biosciences Group, Inc., 1311 Pineview Dr., Morgantown, WV 26505 USA
Phone:  304.292.2226             Fax:  304.292.7101

Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.